Raymond James Financial Inc Denali Therapeutics Inc. Transaction History
Raymond James Financial Inc
- $264 Billion
- Q4 2024
A detailed history of Raymond James Financial Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 26,143 shares of DNLI stock, worth $589,001. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,143Holding current value
$589,001% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
231Shares Held
119MCall Options Held
60.6KPut Options Held
48.4K-
Black Rock Inc. New York, NY13.2MShares$297 Million0.01% of portfolio
-
Baillie Gifford & CO12.3MShares$277 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$252 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$242 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$178 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.02B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...